BOLT Bolt Biotherapeutics Inc
Price (delayed)
$0.401
Market cap
$15.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$32.59M
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach
Highlights
The EPS has grown by 10% YoY and by 3.5% from the previous quarter
The company's net income rose by 9% YoY and by 3% QoQ
The equity is down by 49% YoY and by 21% from the previous quarter
The debt has grown by 39% from the previous quarter and by 25% YoY
Key stats
What are the main financial stats of BOLT
Market
Valuations
Earnings
Shares outstanding
38.34M
Market cap
$15.37M
Enterprise value
$32.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
1.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.24
Revenue
$7.69M
Gross profit
$7.69M
Operating income
-$73.05M
Net income
-$63.12M
EBIT
-$63.12M
EBITDA
-$59.04M
Free cash flow
-$61.18M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.6
Book value per share
$1.49
Revenue per share
$0.2
TBVPS
$2.61
Total assets
$99.63M
Total liabilities
$42.43M
Debt
$25.21M
Equity
$57.2M
Working capital
$34.96M
Debt to equity
0.44
Current ratio
3.2
Quick ratio
3.03
Net debt/EBITDA
-0.29
Margins
Efficiency
Dividend
EBITDA margin
-767.8%
Gross margin
100%
Net margin
-820.8%
Operating margin
-949.9%
Return on assets
-53%
Return on equity
-79.1%
Return on invested capital
-55.2%
Return on capital employed
-75.3%
Return on sales
-820.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BOLT stock price
How has the Bolt Biotherapeutics stock price performed over time
Intraday
4.7%
1 week
-8.86%
1 month
-15.49%
1 year
-71.36%
YTD
-25.06%
QTD
0.25%
Financial performance
How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$7.69M
Gross profit
$7.69M
Operating income
-$73.05M
Net income
-$63.12M
Gross margin
100%
Net margin
-820.8%
The net margin has contracted by 23% from the previous quarter but it has grown by 7% YoY
Bolt Biotherapeutics's operating margin has decreased by 22% from the previous quarter
The revenue fell by 21% QoQ and by 2.4% YoY
Bolt Biotherapeutics's gross profit has decreased by 21% from the previous quarter and by 2.4% YoY
Growth
What is Bolt Biotherapeutics's growth rate over time
Valuation
What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.27
P/S
1.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.24
The EPS has grown by 10% YoY and by 3.5% from the previous quarter
BOLT's P/B is 68% below its 5-year quarterly average of 0.8 and 35% below its last 4 quarters average of 0.4
The equity is down by 49% YoY and by 21% from the previous quarter
The stock's P/S is 39% less than its last 4 quarters average of 3.1
The revenue fell by 21% QoQ and by 2.4% YoY
Efficiency
How efficient is Bolt Biotherapeutics business performance
The ROE has shrunk by 54% YoY and by 14% QoQ
Bolt Biotherapeutics's ROA has decreased by 40% YoY and by 9% from the previous quarter
Bolt Biotherapeutics's ROIC has decreased by 38% YoY and by 7% from the previous quarter
The ROS has contracted by 23% from the previous quarter but it has grown by 7% YoY
Dividends
What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BOLT.
Financial health
How did Bolt Biotherapeutics financials performed over time
The total assets is 135% greater than the total liabilities
The quick ratio has contracted by 39% YoY
The total assets has declined by 38% year-on-year and by 9% since the previous quarter
The debt is 56% less than the equity
BOLT's debt to equity has soared by 144% YoY and by 76% from the previous quarter
The equity is down by 49% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.